Clinical Trial Update: Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluated the experimental agent LLME for reducing the incidence and severity of graft-versus-host disease after hematopoietic stem …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Malignancies

Drugs mentioned

• LLME

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Hematologic Malignancies | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-12-10